Small molecule · Inhibitor of Janus kinase 1 (JAK1) · developed by Pfizer
Abrocitinib is an oral Janus kinase inhibitor that reversibly binds the ATP site of JAK1, showing selectivity over JAK2, JAK3 and TYK2. It is studied in eczema, and the label describes its use in refractory, moderate-to-severe atopic dermatitis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 9, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06807268 | Phase 3 | Eczema | Active not recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Eczema
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →